Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: Natalizumab vs Fingolimod in RRMS
NCT02342704Phase 4Terminated
- Sponsor
- Biogen
- Start
- Nov 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoint: Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions at 52 weeks. Started Nov 2014; status: terminated.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02342704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342704.